Jason Ryan sold $5.0M of WGS
Executive Chairman at GeneDx Holdings Corp.. 39,222 shares at an average of $127.37, traded Aug 27, 2025, filed Aug 27, 2025.
Score components
- +15RoleDirector
- +25Trade size$5.0M at market
- +10Share of holdings soldSold 28% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.3%, 3m +28.2%, 6m -38.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-023190, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 27, 2025 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan 2024 GRAT | -8,818 | $125.07 | $1.1M | 132,538 | Aug 27, 2025 |
| Aug 27, 2025 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan 2024 GRAT | -8,969 | $126.15 | $1.1M | 123,569 | Aug 27, 2025 |
| Aug 27, 2025 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan 2024 GRAT | -5,443 | $127.44 | $694k | 118,126 | Aug 27, 2025 |
| Aug 27, 2025 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan 2024 GRAT | -3,452 | $128.04 | $442k | 114,674 | Aug 27, 2025 |
| Aug 27, 2025 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan 2024 GRAT | -9,890 | $129.59 | $1.3M | 104,784 | Aug 27, 2025 |
| Aug 27, 2025 | SOpen-market sale Class A Common Stockindirect: By Jason Ryan 2024 GRAT | -1,500 | $130.01 | $195k | 103,284 | Aug 27, 2025 |
| Aug 27, 2025 | SOpen-market sale Class A Common Stock | -1,150 | $129.65 | $149k | 11,904 | Aug 27, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 28Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $227k 3,729 shares | -9% | |
| 38Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $638k 10,501 shares | -9% | |
| 23Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $68k 1,266 shares | -3% | |
| 30Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $196k 3,639 shares | -4% | |
| 56Moderate | WGSbuy GeneDx Holdings Corp. | Casdin Capital, LLC director, owner | $11M 200,000 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.